青岛海泰新光科技股份有限公司2025 年半年度报告 公司代码：688677 公司简称：海泰新光 青岛海泰新光科技股份有限公司 青岛海泰新光科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细描述 可能存在的相关风险，敬请查阅第三节"管理层讨论与分析"中有关风险的说明。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人郑安民、主管会计工作负责人汪方华及会计机构负责人（会计主管人员）陈明 明声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 九、 ...

Investment Rating - The report gives a "Buy" rating for the company [3]. Core Views - The company is expected to see significant revenue growth from 2025 to 2027, with projected revenues of CNY 5.66 billion, CNY 7.19 billion, and CNY 9.24 billion, representing year-on-year growth rates of 27.8%, 27.0%, and 28.6% respectively. Net profit attributable to the parent company is forecasted to be CNY 1.79 billion, CNY 2.26 billion, and CNY 2.89 billion for the same years, with growth rates of 32.5%, 26.3%, and 27.6% respectively [3][4]. Company Overview - The company, established in 2003, focuses on the research, development, production, and sales of medical endoscopic instruments and optical products. It integrates optical technology with various fields including medicine, industry, and laser technology [15][24]. - The company has a complete industrial chain from system design to optical processing and system integration, providing high-quality products and services for medical and optical fields [15]. Financial Performance - In 2024, the company achieved a revenue of CNY 4.43 billion, a decrease of 5.90% year-on-year, and a net profit of CNY 1.35 billion, down 7.11% year-on-year. However, in Q1 2025, the company reported a revenue of CNY 1.47 billion, a year-on-year increase of 24.86%, and a net profit of CNY 0.47 billion, up 21.45% year-on-year [18][20]. - The company's gross margin slightly improved to 64.51% in 2024, while the net margin was 30.20% [22]. Market Potential - The report highlights the significant growth potential in the fluorescence endoscope market, with the Chinese hard endoscope market nearing CNY 100 billion in 2024 and a growing domestic production rate [41][42]. - The global fluorescence endoscope market is expected to grow rapidly, with a projected compound annual growth rate of 24.3% [44]. Product Development - The company has successfully launched the new generation of fluorescence endoscopes, which are expected to drive sales growth. The N780 4K fluorescence endoscope system is anticipated to lead market sales [4][25]. - The company has established strong partnerships with major international medical device manufacturers, enhancing its market position [35].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Qindao Haitai Newlight Technology Co., Ltd., particularly in the medical device industry [1][2] - As of June 19, the company's stock closed at 38.36 yuan, with a decline of 2.09%, resulting in a rolling PE ratio of 32.02 times and a total market capitalization of 4.598 billion yuan [1] - The average PE ratio for the medical device industry is 48.08 times, with a median of 36.05 times, placing Qindao Haitai Newlight at the 70th position in the industry ranking [1][2] Group 2 - As of the first quarter of 2025, 26 institutions hold shares in Qindao Haitai Newlight, including 22 funds, 3 other institutions, and 1 social security fund, with a total holding of 57.068 million shares valued at 2.145 billion yuan [1] - The company's main business focuses on the research, development, manufacturing, sales, and service of medical endoscope instruments and optical products, including 4K fluorescence/white light laparoscopes and endoscope light source modules [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 147 million yuan, a year-on-year increase of 24.86%, and a net profit of 46.6887 million yuan, up 21.45%, with a gross profit margin of 64.98% [1]